氨磺必利与阿立哌唑治疗慢性精神分裂症的临床对照研究.docVIP

氨磺必利与阿立哌唑治疗慢性精神分裂症的临床对照研究 　　【摘要】 目的：探讨氨磺必利与阿立哌唑治疗慢性精神分裂症的临床疗效与安全性。方法：选取2014年3月-2015年6月在本院心理科住院的精神分裂症患者78例为研究对象，按随机数字表法分为氨磺必利组与阿立哌唑组，每组39例，分别给予氨磺必利与阿立哌唑治疗8周，于治疗前及治疗2、4、8周末采用阳性与阴性量表（PANSS）评定疗效，药物不良反应量表（TESS）评定不良反应。结果：治疗8周后，氨磺必利组和阿立哌唑组患者总有效率分别为79.49%、74.36%，两组疗效比较差异无统计学意义（P0.05），两组治疗后PANSS评分均明显低于治疗前，且治疗8周后氨磺必利组阴性症状评分高于阿立哌唑组，比较差异均有统计学意义（P0.01或P0.05）；氨磺必利组不良反应发生率69.23%，阿立哌唑组不良反应发生率为43.59%，阿立哌唑组不良反应发生率低于氨磺必利组，比较差异有统计学意义（P0.05）。结论：氨磺必利与阿立哌唑治疗慢性精神分裂症的临床疗效相当，但阿立哌唑不良反应少，更加安全，且对于治疗以阴性症状为主的慢性精神分裂症更具有优势，值得精神科临床推广应用。 　　【关键词】 氨磺必利； 阿立哌唑； 慢性精神分裂症 　　The Controlled Clinical Study on Amisulpride and Aripiprazole in Treatment of Chronic Schizophrenia/XU Hai-chun，ZHANG Chang，WANG Chun-li，et al.//Medical Innovation of China，2016，13（10）：033-036 　　【Abstract】 Objective：To explore the efficacy and safety of Amisulpride and Aripiprazole in the treatment of chronic schizophrenia.Method：Seventy-eight chronic schizophrenic inpatients admitted to our hospital from March 2014 to June 2015 were selected and divided into Amisulpride group and Aripiprazole group according to the random number table，with 39 patients in each group.All patients were given Amisulpride or Aripiprazole for 8 weeks，the efficacy of different drugs as well as the safety and incidence of adverse events were evaluated by positive and negative symptom scale（PANSS） and treatment emergent symptom scale（TESS） respectively before treatment and at the 2nd，4th，8th week after treatment.Result：The effective rate was 79.49% in the Amisulpride group and 74.36% in the Aripiprazole group，the difference was not statistically significant（P0.05）.The scores of both groups in PANSS after treatment were significantly lower than before treatment，however，8 weeks after treatment，the score of negative symptoms in PANSS of the Amisulpride group was higher than that of the Aripiprazole group，the differences were statistically significant （P0.05 or P0.01）.The incidence of adverse events was 69.23% in the Amisulpride group and 43.59% in the Aripi